ClinicalTrials.gg
Not yet recruitingNCT07663552Updated Jun 23, 2026

Retro-Prospective Postmarket Clinical Study For FX Shoulder Solutions Long Cemented HUMELOCK II®

An observational study in Humeral Fracture, Proximal and Revision of a Shoulder Prosthesis, sponsored by FX Solutions. Not yet recruiting at 4 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-23.

Sponsored by FX Solutions · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

This study takes place in the framework of the PostMarket Clinical Follow-up plan of the HUMELOCK II(r) long cemented humeral stem (shoulder prosthesis) commercialized by FX SHOULDER SOLUTIONS.

The included cases will be followed for 10 years after index surgery. Primary objective is the assessment in real life of the revision rate of the shoulder systems at long-term.

Secondary objectives are

  • Revision rate at each post op visit
  • Range of motion at each post op visit
  • Constant Score, American Shoulder and Elbow Surgeons Shoulder Score (ASES), Pain score (VAS) at each post op visit
  • Radiological assessment of implant positioning through geometrical parameters at each post op visit
  • Incidence of complications at each post op visit
Read the detailed description

Recruitment of patients can be retrospective or prospective, mainly retrospectively. Follow-up will be prospective from the date of study inception.

Recruitment will include all cases available at the selected investigation centers.

Prospective follow-up of the patients after inclusion at 6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years , 7 years and 10 years postoperatively.

02

Conditions studied

  • Humeral Fracture, Proximal
  • Revision of a Shoulder Prosthesis

Browse trials for

03

In context

Shoulder Fractures

113 studies on the registry are indexed under Shoulder Fractures; 30 are open to participants now.

This study's planned enrollment of 40 is below the median of 97 across 60 observational studies indexed under Shoulder Fractures.

Browse Shoulder Fractures studies →

Lead sponsor

FX Solutions is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Study population is issued from investigators' patient population.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication for hemi anatomic or total reversible shoulder replacement with Long Cemented HUMELOCK II® humeral stem for Trauma or Revision indication, according to its IFU and surgical technique.
  • Patient aged 18 years and above
  • Patient insured with a social security system
  • Has been informed and did consent to participate to the study.

Exclusion criteria

Exclusion Criteria:

  • Neurological pathologies compromising the shoulder stability
  • Morbid obesity
  • Muscular deficiencies impairing the shoulder joint
05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Long Cemented HUMELOCK II® Hemi Anatomic Shoulder System for Trauma Indications

    Subjects treated with cemented long HUMELOCK II® Hemi Anatomic Shoulder System for traumatic indications

    Procedure: Shoulder arthroplasty

  • Group 2: Long Cemented HUMELOCK II® Hemi Anatomic Shoulder System for Revision Indications

    Subjects treated with cemented long HUMELOCK II® Hemi Anatomic Shoulder System for revision indications

    Procedure: Shoulder arthroplasty

  • Group 3: Long Cemented HUMELOCK II® Reversible Total Shoulder System for Trauma Indications

    Subjects treated with cemented long HUMELOCK II® Reversible Shoulder System for traumatic indications

    Procedure: Shoulder arthroplasty

  • Group 4: Long Cemented HUMELOCK II® Reversible Total Shoulder System for Revision Indications

    Subjects treated with cemented long HUMELOCK II® Reversible Shoulder System for revision indications

    Procedure: Shoulder arthroplasty

Interventions

  • ProcedureShoulder arthroplasty

    Hemi anatomical (HSA) or reversed (RSA) shoulder arthroplasties.

06

What researchers measure

Primary outcomes

  1. Revision rate (KM) at 10 years postoperative

    Survival rate (%) at 10 years calculated by means of Kaplan-Meier method

    Time frame: at the end of the postoperative follow-up period of 10 years

Secondary outcomes

  1. Revision rate (KM) at each postoperative visit

    Survival rate (%) at each postoperative visit calculated by means of Kaplan-Meier method

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years)

  2. Range of Motions at each postoperative visit

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

  3. Constant-Murley score at each postopererative visit

    The Constant-Murley score (CMS) is a 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient. The higher the score, the higher the quality of the function and the lower the pain is.

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

  4. ASES score at each postoperative visit

    ASES (American Shoulder and Elbow Surgeons) score ranges from 0 to 100, with 0 the lowest level of function and 100 the highest level of function.

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

  5. VAS pain at each postoperative visit

    The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be').

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

  6. Radiological assessment of implant positioning at each postoperative visit

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

  7. Incidence of complications at each postoperative visit

    Time frame: At each postoperative visit (6 weeks, 3 or 6 months, 1 year, 2 years, 3 years, 5 years, 7 years, 10 years)

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Dec 2036, 125 months later.

Of 30 observational studies under Shoulder Fractures, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 109. This study's planned 125 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2026
First posted
Jun 23, 2026
StartEst.
Jul 2026
Primary completionEst.
Dec 31, 2036
CompletionEst.
Jun 2037
Last update
Jun 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07663552
Lead sponsor
FX Solutions
Responsible party
Sponsor
First posted
Jun 23, 2026
Start date
Jul 2026 (estimated)
Primary completion
Dec 31, 2036 (estimated)
Completion
Jun 2037 (estimated)
Last update
Jun 23, 2026

Study contacts

Kathy TRIER, PhD
Contact
ktrier@fxshouldersolutions.com
800-280-0775
Gabriel GUEUGNON
Contact
+33 6 09 25 38 08

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion